Clinical Study

Nektar 18-214-10- A Phase 2, Randomized, Non-Comparative, Open-Label Study Of Nktr-214 In Combination With Nivolumab And Of Chemotherapy In Cisplatin Ineligible, Locally Advanced Or Metastatic Urothelial Cancer Patients With Low Pd-L1 Expression

Posted Date: Feb 24, 2020

  • Investigator: Shuchi Gulati
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The primary goal of this study is to evaluate the anti-tumor activity of NKTR-214 in combination with nivolumab by assessing the ORR by RECIST 1.1 per blinded independent central review (BICR) in patients whose tumors have low PD-L1 expression


To Be Eligible: Must Have Documented Urothelial Cell Carcinoma, Ecog = 2, Measurable Disease, Prior Systemic Chemotherapy Or Investigational Agent For Study Cancer, No Other Active Malignancy Within 3 Years


Urothelial Cancer, Oncology, Gu

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.